|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Body A, Prenen H, Latham S, Lam M,
Tipping-Smith S, Raghunath A and Segelov E: The Role of Neoadjuvant
Chemotherapy in Locally Advanced Colon Cancer. Cancer Manag Res.
13:2567–2579. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yaghoubi N, Soltani A, Ghazvini K,
Hassanian SM and Hashemy SI: PD-1/ PD-L1 blockade as a novel
treatment for colorectal cancer. Biomed Pharmacother. 110:312–318.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Juneja VR, McGuire KA, Manguso RT, LaFleur
MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor
cells is sufficient for immune evasion in immunogenic tumors and
inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masugi Y, Nishihara R, Yang J, Mima K, da
Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, et al: Tumour
CD274 (PD-L1) expression and T cells in colorectal cancer. Gut.
66:1463–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pyo JS, Ko SH, Ko YS and Kim NY:
Clinicopathological significance of PD-L1 expression in colorectal
cancer: Impact of PD-L1 expression on pFOXO1 expression. Pathol Res
Pract. 216:1527642020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, He M, Zhou Y, Yang C, Wei S, Bian X,
Christopher O and Xie L: The prognostic and clinicopathological
roles of PD-L1 expression in colorectal cancer: A systematic review
and meta-analysis. Front Pharmacol. 10:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sinicrope FA, Foster NR, Thibodeau SN,
Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C,
Moore MJ, et al: DNA mismatch repair status and colon cancer
recurrence and survival in clinical trials of 5-fluorouracil-based
adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolk K, Witte E, Witte K, Warszawska K and
Sabat R: Biology of interleukin-22. Semin Immunopathol. 32:17–31.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang R, Wang H, Deng L, Hou J, Shi R, Yao
M, Gao Y, Yao A, Wang X, Yu L and Sun B: IL-22 is related to
development of human colon cancer by activation of STAT3. BMC
Cancer. 13:592013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun D, Lin Y, Hong J, Chen H, Nagarsheth
N, Peng D, Wei S, Huang E, Fang J, Kryczek I and Zou W: Th22 cells
control colon tumorigenesis through STAT3 and Polycomb Repression
complex 2 signaling. Oncoimmunology. 5:e10827042015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kryczek I, Lin Y, Nagarsheth N, Peng D,
Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al:
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3
transcription factor activation and induction of the
methyltransferase DOT1L. Immunity. 40:772–784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Xiang F, Huang Y, Shi L, Hu C, Yang
Y, Wang D, He N, Tao K, Wu K and Wang G: Interleukin-22 promotes
aerobic glycolysis associated with tumor progression via targeting
hexokinase-2 in human colon cancer cells. Oncotarget.
8:25372–25383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen S, Crabill GA, Pritchard TS, McMiller
TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating
PD-L1 expression on tumor and immune cells. J Immunother Cancer.
7:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seki N, Kan-O K, Matsumoto K, Fukuyama S,
Hamano S, Tonai K, Ota K, Inoue H and Nakanishi Y: Interleukin-22
attenuates double-stranded RNA-induced upregulation of PD-L1 in
airway epithelial cells via a STAT3-dependent mechanism. Biochem
Biophys Res Comm. 494:242–248. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eppihimer MJ, Gunn J, Freeman GJ,
Greenfield EA, Chernova T, Erickson J and Leonard JP: Expression
and regulation of the PD-L1 immunoinhibitory molecule on
microvascular endothelial cells. Microcirculation. 9:133–145. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Yang L, Huang F, Zhang Q, Liu S,
Ma L and You Z: Inflammatory cytokines IL-17 and TNF-α up-regulate
PD-L1 expression in human prostate and colon cancer cells. Immunol
Lett. 184:7–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qian J, Wang C, Wang B, Yang J, Wang Y,
Luo F, Xu J, Zhao C, Liu R and Chu Y: The IFN-γ/PD-L1 axis between
T cells and tumor microenvironment: Hints for glioma
anti-PD-1/PD-L1 therapy. J Neuroinflammation. 15:2902018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha
JH, Wang HL, Yang WH, Yen EY, Chang WC, et al: IL-6/JAK1 pathway
drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
J Clin Invest. 129:3324–3338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hernandez P, Gronke K and Diefenbach A: A
catch-22: Interleukin-22 and cancer. Eur J Immunol. 48:15–31. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wolk K, Witte E, Wallace E, Döcke WD, Kunz
S, Asadullah K, Volk HD, Sterry W and Sabat R: IL-22 regulates the
expression of genes responsible for antimicrobial defense, cellular
differentiation, and mobility in keratinocytes: A potential role in
psoriasis. Eur J Immunol. 36:1309–1323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eyerich S, Eyerich K, Pennino D, Carbone
T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann
C, Behrendt H, et al: Th22 cells represent a distinct human T cell
subset involved in epidermal immunity and remodeling. J Clin
Invest. 119:3573–3585. 2009.PubMed/NCBI
|
|
26
|
Galoczova M, Coates P and Vojtesek B:
STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett.
23:122018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fathi N, Rashidi G, Khodadadi A, Shahi S
and Sharifi S: STAT3 and apoptosis challenges in cancer. Int J Biol
Macromol. 117:993–1001. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li P, Huang T and Zou Q: FGFR2 promotes
expression of PD-L1 in colorectal cancer via the JAK/STAT3
signaling pathway. J Immunol. 202:3065–3075. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jahangiri A and Dadmanesh M: STAT3
inhibition reduced PD-L1 expression and enhanced antitumor immune
responses. J Cell Physiol. 235:9457–9463. 2020. View Article : Google Scholar : PubMed/NCBI
|
